Scribe Therapeutics Inc. SCTX

SCTX Company Overview

Scribe Therapeutics Inc. is a privately held biotechnology company focused on developing next-generation CRISPR-based genetic medicines. The company operates within the gene editing, genomic medicine, and biotechnology industries, with a primary emphasis on engineering highly specific and programmable CRISPR tools for therapeutic applications. Scribe’s core technology platform centers on proprietary engineered CRISPR enzymes designed to improve precision, reduce off-target editing, and enable broader therapeutic utility across in vivo and ex vivo applications.

The company’s primary business drivers include research collaborations, platform licensing, and the development of internal therapeutic programs targeting genetic diseases. Scribe has positioned itself as a differentiated gene editing company through its engineered CRISPR systems, including its “X-Editing” technology platform, which aims to improve editing accuracy and delivery efficiency compared with earlier-generation CRISPR systems. The company was founded in 2018 by CRISPR pioneer Jennifer Doudna alongside scientific collaborators including Benjamin Oakes and David Savage. Since inception, Scribe has evolved from a platform-engineering company into a therapeutics-focused organization with partnerships spanning pharmaceutical development and genomic medicine.